Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Journal of Clinical Lipidology
Year: 2009  |  Volume: 3  |  Issue: 6  |  Page No.: 385 - 392

Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring

James McKenney, Sanjay K. Gandhi, Kathleen M. Fox and Robert L. Ohsfeldt    

Abstract:

Background

Clinical guidelines have recommended a LDL-C goal of <100 mg/dL for high-risk individuals and lipid-modifying therapy for patients not reaching this goal.

Objective

This investigation assessed low-density lipoprotein cholesterol (LDL-C) levels and treatment patterns among patients diagnosed with atherosclerosis with or without a previous cardiovascular disease (CVD) event.

Methods

We conducted a retrospective study by using claims data from a national health plan that included patients with ≥ 1 medical claim for atherosclerosis (ICD-9 of 440.xx, 414.x, 437.0, 437.1, or 437.3) between January 2004 and March 2006. Use of lipid-modifying medications at the time of diagnosis and thereafter, patient demographics, comorbid conditions, baseline, and postdiagnosis LDL-C were assessed.

Results

There were 311,567 patients who had an atherosclerosis ICD-9 code, 46% of whom had a previous CVD event. Among patients with an atherosclerosis diagnosis and CVD event, lipid-modifying therapy was received by 50% before diagnosis and 57% after diagnosis, compared with 37% before and 48% after diagnosis for patients with an atherosclerosis diagnosis and no previous CVD event. Of the patients with baseline LDL-C (15%, n=46,923), 44% had an LDL-C <100 mg/dL at diagnosis; of those with LDL-C ≥ 100 mg/dL, only 54% received lipid-modifying therapy and only 64% achieved an LDL-C <100 mg/dL in the 12 succeeding months. Among patients with baseline and postdiagnosis LDL-C values (n=24,724), 55% had a baseline LDL-C ≥ 100 mg/dL and 46% had a baseline non-HDL-C ≥ 130 mg/dL.

Conclusions

In conclusion, many patients in a managed care plan diagnosed with atherosclerosis with or without a previous CVD event present opportunities for better lipid management. Healthcare providers should evaluate more aggressive lipid management interventions for these patients for potential downstream cardiovascular benefits.

View Fulltext    |   Related Articles   |   Back
 
 
   
 
 
 
  Related Articles

No Article Found
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility